Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT05648110
Registration number
NCT05648110
Ethics application status
Date submitted
30/11/2022
Date registered
13/12/2022
Date last updated
26/06/2024
Titles & IDs
Public title
Study Understanding Pre-Exposure pRophylaxis of NOVel Antibodies (SUPERNOVA) Sub-study: Study Understanding Pre-Exposure pRophylaxis of NOVel Antibodies (SUPERNOVA) Sub-study
Query!
Scientific title
A Phase I/III Randomized, Double-blind Study to Evaluate the Safety, Efficacy and Neutralizing Activity of AZD5156/AZD3152 for Pre-exposure Prophylaxis of COVID-19 in Participants With Conditions Causing Immune Impairment. Sub-study: Phase II Open Label Sub-study to Evaluate the Safety, PK, and Neutralizing Activity of AZD3152 for Pre-exposure Prophylaxis of COVID-19
Query!
Secondary ID [1]
0
0
2022-002378-95
Query!
Secondary ID [2]
0
0
D7000C00001
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
SUPERNOVA
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
COVID-19, SARS-CoV-2
0
0
Query!
Condition category
Condition code
Infection
0
0
0
0
Query!
Other infectious diseases
Query!
Respiratory
0
0
0
0
Query!
Other respiratory disorders / diseases
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Other - AZD5156 (Parent study Sentinel Safety Cohort)
Treatment: Other - Placebo (Parent study Sentinel Safety Cohort)
Treatment: Other - EVUSHELDâ„¢ (Parent study Main Cohort)
Treatment: Other - AZD3152 (Parent study Main Cohort)
Treatment: Other - Placebo (Parent study Main Cohort)
Treatment: Other - AZD3152 (Sub-study)
Treatment: Other - AZD7442 - EVUSHELDâ„¢ (Sub-study)
Treatment: Other - AZD7442 (EVUSHELDâ„¢) (Sub-study) Immunocompromised participants offered AZD3152
Experimental: Parent study Sentinel Safety Cohort - Subcohort 1a Gluteal - AZD5156 - The Sentinel Safety Cohort of the Parent Study will enroll 56 healthy adults, 18 to 55 years of age, who will be randomized to receive AZD5156 (40 participants) or placebo (16 participants). Participants will be randomized to receive study intervention IM either in the gluteal or the anterolateral thigh. Dosing within the Sentinel Safety Cohort will be staggered, with participants allocated sequentially to 4 subcohorts (1a, 1b, 2a, and 2b).
Placebo comparator: Parent study Sentinel Safety Cohort - Subcohort 1a Gluteal - Placebo - The Sentinel Safety Cohort of the Parent study will enroll 56 healthy adults, 18 to 55 years of age, who will be randomized to receive AZD5156 (40 participants) or placebo (16 participants). Participants will be randomized to receive study intervention IM either in the gluteal or the anterolateral thigh. Dosing within the Sentinel Safety Cohort will be staggered, with participants allocated sequentially to 4 subcohorts (1a, 1b, 2a, and 2b).
Experimental: Parent study Sentinel Safety Cohort - Subcohort 1b Thigh - AZD5156 - The Sentinel Safety Cohort of the Parent study will enroll 56 healthy adults, 18 to 55 years of age, who will be randomized to receive AZD5156 (40 participants) or placebo (16 participants). Participants will be randomized to receive study intervention IM either in the gluteal or the anterolateral thigh. Dosing within the Sentinel Safety Cohort will be staggered, with participants allocated sequentially to 4 subcohorts (1a, 1b, 2a, and 2b).
Placebo comparator: Parent study Sentinel Safety Cohort - Subcohort 1b Thigh - Placebo - The Sentinel Safety Cohort of the Parent study will enroll 56 healthy adults, 18 to 55 years of age, who will be randomized to receive AZD5156 (40 participants) or placebo (16 participants). Participants will be randomized to receive study intervention IM either in the gluteal or the anterolateral thigh. Dosing within the Sentinel Safety Cohort will be staggered, with participants allocated sequentially to 4 subcohorts (1a, 1b, 2a, and 2b).
Experimental: Parent study Sentinel Safety Cohort - Subcohort 2a Gluteal- AZD5156 - The Sentinel Safety Cohort of the Parent study will enroll 56 healthy adults, 18 to 55 years of age, who will be randomized to receive AZD5156 (40 participants) or placebo (16 participants). Participants will be randomized to receive study intervention IM either in the gluteal or the anterolateral thigh. Dosing within the Sentinel Safety Cohort will be staggered, with participants allocated sequentially to 4 subcohorts (1a, 1b, 2a, and 2b).
Placebo comparator: Parent study Sentinel Safety Cohort - Subcohort 2a Gluteal - Placebo - The Sentinel Safety Cohort of the Parent study will enroll 56 healthy adults, 18 to 55 years of age, who will be randomized to receive AZD5156 (40 participants) or placebo (16 participants). Participants will be randomized to receive study intervention IM either in the gluteal or the anterolateral thigh. Dosing within the Sentinel Safety Cohort will be staggered, with participants allocated sequentially to 4 subcohorts (1a, 1b, 2a, and 2b).
Experimental: Parent study Sentinel Safety Cohort - Subcohort 2b Thigh - AZD5156 - The Sentinel Safety Cohort of the Parent study will enroll 56 healthy adults, 18 to 55 years of age, who will be randomized to receive AZD5156 (40 participants) or placebo (16 participants). Participants will be randomized to receive study intervention IM either in the gluteal or the anterolateral thigh. Dosing within the Sentinel Safety Cohort will be staggered, with participants allocated sequentially to 4 subcohorts (1a, 1b, 2a, and 2b).
Placebo comparator: Parent study Sentinel Safety Cohort - Subcohort 2b Thigh - Placebo - The Sentinel Safety Cohort of the Parent study will enroll 56 healthy adults, 18 to 55 years of age, who will be randomized to receive AZD5156 (40 participants) or placebo (16 participants). Participants will be randomized to receive study intervention IM either in the gluteal or the anterolateral thigh. Dosing within the Sentinel Safety Cohort will be staggered, with participants allocated sequentially to 4 subcohorts (1a, 1b, 2a, and 2b).
Experimental: Parent study Main Cohort - AZD3152 - The Main Cohort of the Parent study will enroll approximately 3200 participants. Dosing in the Main Cohort will be staggered, so that it starts with adult participants aged 18 years and older, with no adolescent participants dosed in the Main Cohort until safety data from Visit 2a (Day 8) and Visit 2b (Day 15) have been reviewed by the DSMB for at least 80 adult Main Cohort participants (which will include at least 40 participants who have received AZD3152). Participants in the Main Cohort will be randomized 1:1 to receive AZD3152 300 mg or comparator administered IM in the anterolateral thigh on Day 1. Participants will receive a second dose of their original randomized study intervention (ie, active treatment or comparator) 6 months after Visit 1.
Active comparator: Parent study Main Cohort - EVUSHELDâ„¢ - Participants in the Main Cohort of the Parent study will be randomized 1:1 to receive AZD3152 300 mg or comparator administered IM in the anterolateral thigh on Day 1. Participants will receive a second dose of their original randomized study intervention (ie, active treatment or comparator) 6 months after Visit 1.
At the request of regulatory authorities the active comparator will be changed to placebo. As the comparator is given on two occasions, this means that a participant randomized to the comparator arm may receive (a) two doses of EVUSHELD, (b) a dose of EVUSHELD and a dose of placebo, or (c) two doses of placebo.
Placebo comparator: Parent study Main Cohort - Placebo - Participants in the Main Cohort of the Parent study will be randomized 1:1 to receive AZD3152 300 mg or comparator administered IM in the anterolateral thigh on Day 1. Participants will receive a second dose of their original randomized study intervention (ie, active treatment or comparator) 6 months after Visit 1.
At the request of regulatory authorities the active comparator will be changed to placebo. As the comparator is given on two occasions, this means that a participant randomized to the comparator arm may receive (a) two doses of EVUSHELD, (b) a dose of EVUSHELD and a dose of placebo, or (c) two doses of placebo.
Experimental: Sub-study - AZD3152 - This sub-study will enroll approximately 450 participants, = 18 years of age with a minimum weight of 40 kg. An initial Sentinel Safety Cohort will include 12 healthy volunteers; all other participants in the study will be either immunocompromised or immunocompetent (including healthy participants) with all degrees of SARS-CoV-2 infection risk.
Active comparator: Sub-study - AZD7442 (EVUSHELDâ„¢) - This sub-study will enroll approximately 450 participants, = 18 years of age with a minimum weight of 40 kg. An initial Sentinel Safety Cohort will include 12 healthy volunteers; all other participants in the study will be either immunocompromised or immunocompetent (including healthy participants) with all degrees of SARS-CoV-2 infection risk.
Experimental: Sub-study - AZD7442 (EVUSHELDâ„¢) Immunocompromised participants offered AZD3152 1200mg IV - This sub-study will enroll approximately 450 participants, = 18 years of age with a minimum weight of 40 kg. An initial Sentinel Safety Cohort will include 12 healthy volunteers; all other participants in the study will be either immunocompromised or immunocompetent (including healthy participants) with all degrees of SARS-CoV-2 infection risk.
Treatment: Other: AZD5156 (Parent study Sentinel Safety Cohort)
600 mg AZD5156 consisting of 300 mg AZD1061 at 100 mg/mL and 300 mg AZD3152 at 150 mg/mL
3 mL of AZD1061 2 mL of AZD3152 IM on Visit 1 Day 1
Treatment: Other: Placebo (Parent study Sentinel Safety Cohort)
single dose of Placebo (3 mL + 2 mL) IM
Treatment: Other: EVUSHELDâ„¢ (Parent study Main Cohort)
600 mg EVUSHELDâ„¢/AZD7442 consisting of 300 mg AZD1061 and 300 mg AZD8895, both at 100 mg/mL
2 IM injections (thigh) of 3 mL each IM on Visit 1 Day 1 and on Visit 5 Day 181
Treatment: Other: AZD3152 (Parent study Main Cohort)
300 mg AZD3152 at 150 mg/mL
1 IM injection (thigh) of 2 mL of AZD3152 on Visit 1 Day 1 and on Visit 5 Day 181
Treatment: Other: Placebo (Parent study Main Cohort)
Single doses of 0.9% sodium chloride 2 mL IM for injection on Visit 1 Day 1 and Visit 5 Day 181
Treatment: Other: AZD3152 (Sub-study)
Single dose of 1200 mg IV at Visit 1 Day 1
Treatment: Other: AZD7442 - EVUSHELDâ„¢ (Sub-study)
Single dose 300 mg IM administered on Visit 1 Day 1
Treatment: Other: AZD7442 (EVUSHELDâ„¢) (Sub-study) Immunocompromised participants offered AZD3152
Single dose of AZD7442 (EVUSHELDâ„¢) 300 mg IM
Query!
Intervention code [1]
0
0
Treatment: Other
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Parent study - Sentinel Safety Cohort: To evaluate the safety of AZD5156
Query!
Assessment method [1]
0
0
Occurence of AEs, SAEs, MAAEs, and AESIs will be collected throughout the study
Query!
Timepoint [1]
0
0
AEs will be collected from IMP administration approximately 90 days following. AESIs will be collected from IMP administration through to Visit 11 (Day 361). SAEs and MAAEs will be collected up to Visit 11 (Day 361).
Query!
Primary outcome [2]
0
0
Parent study - Main Cohort: To evaluate the safety of AZD3152 and EVUSHELD and/or placebo
Query!
Assessment method [2]
0
0
Occurrence of AEs, SAEs, MAAEs, and AESIs will be collected throughout the study
Query!
Timepoint [2]
0
0
Occurrence of AEs collected through approximately 90 days after each IMP administration through to Visit 10 (Day 451). SAEs and MAAEs will be collected up to Visit 10 (Day 451).
Query!
Primary outcome [3]
0
0
Parent study-Main cohort: To compare the efficacy of AZD3152 to EVUSHELD and/or placebo in the prevention of symptomatic COVID 19 caused by any SARS-CoV-2 variant
Query!
Assessment method [3]
0
0
Endpoint: Confirmed symptomatic COVID-19 case, classified as a binary outcome incorporating the time from the first dose of IMP until a participant develops their first symptoms for COVID-19 or are censored. Summary measure: Prophylactic efficacy, calculated as 1 - Hazard Ratio (HR) (AZD3152 versus EVUSHELD and/or placebo) using a hazard regression model.
Query!
Timepoint [3]
0
0
Confirmed symptomatic COVID-19 case is evaluated from first dose up to 181 days after last dose. For participants that receive two doses, the evaluation period would be approximately 361 days.
Query!
Primary outcome [4]
0
0
Parent study - Main cohort: To compare the efficacy of AZD3152 to EVUSHELD and/or placebo in the prevention of symptomatic COVID 19 attributable to matched variants (variants that do not contain the F456L mutation)
Query!
Assessment method [4]
0
0
Endpoint: Confirmed symptomatic COVID-19 case attributable to matched variants, classified as a binary outcome incorporating the time from the first dose of IMP until a participant develops their first symptoms for COVID-19 or are censored. Summary measure: Prophylactic efficacy, calculated as 1 - Hazard Ratio (HR) (AZD3152 versus EVUSHELD and/or placebo) using a hazard regression model.
Query!
Timepoint [4]
0
0
Confirmed symptomatic COVID-19 case is evaluated from first dose up to 181 days after last dose. For participants that receive two doses, the evaluation period would be approximately 361 days.
Query!
Primary outcome [5]
0
0
Sub-study: To evaluate the safety of AZD3152 and EVUSHELD
Query!
Assessment method [5]
0
0
Occurrence of AEs collected through 29 days after IMP administration for the primary analysis.
Query!
Timepoint [5]
0
0
SAEs, MAAEs, and AESIs collected throughout the study for the final analysis.
Query!
Primary outcome [6]
0
0
Sub-study: To compare the SARS-CoV-2 nAb responses to a current VOC following AZD3152 administration vs SARS-CoV-2 nAb responses to prior variants following EVUSHELD administration
Query!
Assessment method [6]
0
0
SARS-CoV-2 nAb responses to a current VOC following AZD3152 administration vs SARS-CoV-2 nAb responses to prior variants following EVUSHELD administration.
Query!
Timepoint [6]
0
0
Predicted GMT ratio of SARS-CoV-2 nAbs between the treatment arms at Visit 3 (Day 29) for the variant that each IMP is intended to neutralize.
Query!
Secondary outcome [1]
0
0
Parent study - Sentinel Safety Cohort: To characterize the Pharmacokinetics of AZD5156 (AZD1061 and AZD3152) in serum.
Query!
Assessment method [1]
0
0
AZD5156 (AZD1061 and AZD3152) serum concentrations at each visit.
Query!
Timepoint [1]
0
0
Samples will be collected from Visit 1 (Day 1) up to Visit 11 (Day 361).
Query!
Secondary outcome [2]
0
0
Parent study - Sentinel Safety Cohort: To characterize the Pharmacokinetics parameter of maximum concentration (Cmax) of AZD5156 (AZD1061 and AZD3152) in serum
Query!
Assessment method [2]
0
0
To describe maximum concentration (Cmax) for AZD5156 (AZD1061 and AZD3152).
Query!
Timepoint [2]
0
0
Samples will be collected from Visit 1 (Day 1) up to Visit 11 (Day 361)
Query!
Secondary outcome [3]
0
0
Parent study - Sentinel Safety Cohort: To characterize the Pharmacokinetics parameter of time to maximum serum concentration (tmax) of AZD5156 (AZD1061 and AZD3152) in serum
Query!
Assessment method [3]
0
0
To describe time to maximum serum concentration (tmax) for AZD5156 (AZD1061 and AZD3152).
Query!
Timepoint [3]
0
0
Samples will be collected from Visit 1 (Day 1) up to Visit 11 (Day 361).
Query!
Secondary outcome [4]
0
0
Parent study - Sentinel Safety Cohort: To characterize the Pharmacokinetics parameter of terminal half-life (t½) of AZD5156 (AZD1061 and AZD3152) in serum
Query!
Assessment method [4]
0
0
To describe terminal half-life (t½) for AZD5156 (AZD1061 and AZD3152).
Query!
Timepoint [4]
0
0
Samples will be collected from Visit 1 (Day 1) up to Visit 11 (Day 361).
Query!
Secondary outcome [5]
0
0
Parent study - Sentinel Safety Cohort: To characterize the Pharmacokinetics parameter of area under the concentration-time curve at the last measured time point (AUClast) of AZD5156 (AZD1061 and AZD3152) in serum
Query!
Assessment method [5]
0
0
To describe area under the concentration-time curve at the last measured time point (AUClast) for AZD5156 (AZD1061 and AZD3152).
Query!
Timepoint [5]
0
0
Samples will be collected from Visit 1 (Day 1) up to Visit 11 (Day 361).
Query!
Secondary outcome [6]
0
0
Parent study - Sentinel Safety Cohort: To characterize the Pharmacokinetics parameter of area under the concentration-time curve from time zero extrapolated to infinity (AUCinf) of AZD5156 (AZD1061 and AZD3152) in serum
Query!
Assessment method [6]
0
0
To describe area under the concentration-time curve from time zero extrapolated to infinity (AUCinf) for AZD5156 (AZD1061 and AZD3152).
Query!
Timepoint [6]
0
0
Samples will be collected from visit 1 (Day 1) up to visit 11 (Day 361).
Query!
Secondary outcome [7]
0
0
Parent study - Sentinel Safety Cohort: To evaluate the ADA responses to AZD5156, AZD3152, and AZD1061 in serum
Query!
Assessment method [7]
0
0
Incidence of ADA to AZD5156, AZD3152, and AZD1061, ADA titers
Query!
Timepoint [7]
0
0
Samples will be collected from Visit 1 (Day 1) up to Visit 11 (Day 361)
Query!
Secondary outcome [8]
0
0
Parent study - Main Cohort: To compare the nAb responses to the SARS-CoV-2 variants Alpha, Omicron BA.2, Omicron BA.4/5 and/or Omicron XBB.1.5 in serum following AZD3152 and EVUSHELD and/or placebo administration
Query!
Assessment method [8]
0
0
GMT and GMFR ratio of SARS-CoV-2 nAbs between the treatment arms at Visit 3 (Day 29).
Descriptive statistics for GMTs and GMFRs will be provided.
Query!
Timepoint [8]
0
0
Visit 3 (Day 29)
Query!
Secondary outcome [9]
0
0
Parent study - Main Cohort: To describe the incidence of symptomatic COVID-19, severe COVID-19, COVID-19 related hospitalization, and COVID-19 related death in participants receiving study intervention
Query!
Assessment method [9]
0
0
Incidence of a post-treatment:
* Symptomatic COVID-19 case (negative RT-PCR at baseline to positive at any time up to 6 and 12 months) caused by any SARS-CoV-2 variant
* Symptomatic COVID-19 case (negative RT-PCR at baseline to positive at any time up to 6 and 12 months) caused by any SARS-CoV-2 matched variants
* Severe COVID-19 caused by any SARS-CoV-2 variant
* Severe COVID-19 caused by any SARS-CoV-2 matched variants
* Composite of COVID-19 related hospitalization and/or COVID-19 related death (WHO COVID-19 Clinical Progression Scale score = 4)
* COVID-19 related hospitalization (separately)
* COVID-19 related death (separately)
Query!
Timepoint [9]
0
0
COVID-19 incidence variables to be evaluated through Visit 9 (Day 361)
Query!
Secondary outcome [10]
0
0
Parent study - Main Cohort: To characterize the Pharmacokinetics (PK)of the AZD3152 and AZD7442 (AZD1061 and AZD8865) in serum concentrations at each visit.
Query!
Assessment method [10]
0
0
AZD3152 and AZD7442 (AZD1061 and AZD8895) serum concentrations at each visit.
Query!
Timepoint [10]
0
0
Samples will be collected from Visit 1 (Day 1) up to Visit 9 (Day 361)
Query!
Secondary outcome [11]
0
0
Parent study - Main Cohort: To evaluate the Anti-drug Antibodies (ADA) responses to AZD3152 and AZD7442 in serum
Query!
Assessment method [11]
0
0
Incidence of Anti-drug Antibodies (ADA) to AZD3152, AZD7442, AZD1061, and AZD8895, ADA titers
Query!
Timepoint [11]
0
0
Samples will be collected from Visit 1 (Day 1) up to Visit 9 (Day 361)
Query!
Secondary outcome [12]
0
0
Sub-study: To characterize the Pharmacokinetics of AZD3152 and AZD7442 (EVUSHELD) in serum
Query!
Assessment method [12]
0
0
AZD3152, AZD7442 (EVUSHELD), cilgavimab, and tixagevimab concentrations in serum, over time
Query!
Timepoint [12]
0
0
Samples will be collected from Visit 1 (Day 1) up to Visit 5 (Day 181).
Query!
Secondary outcome [13]
0
0
Sub-study:To evaluate the ADA response to AZD3152 and AZD7442 (EVUSHELD) in serum
Query!
Assessment method [13]
0
0
Incidence of ADA to AZD3152, AZD7442 (EVUSHELD), cilgavimab, and tixagevimab; ADA titers
Query!
Timepoint [13]
0
0
Samples will be collected from Visit 1 (Day 1) up to Visit 5 (Day 181).
Query!
Eligibility
Key inclusion criteria
Parent study - Sentinel Safety Cohort Participants (Phase I):
Parent study - Sentinel Cohort
* Healthy participants according to medical history, physical examination, baseline safety laboratory tests, and screening parameters, according to the judgment of the investigator, with no concomitant disease or concomitant medication (except for medication specifically permitted by the protocol).
* Age 18 to 55 years at the time of signing the informed consent.
* Negative rapid antigen test at Visit 1.
* Weight = 45 kg and = 110 kg at screening.
Parent study - Sentinel Cohort
Query!
Minimum age
12
Years
Query!
Query!
Maximum age
130
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
Yes
Query!
Key exclusion criteria
* Women who are pregnant, lactating, or of childbearing potential and not using a highly effective method of contraception or abstinence from at least 4 weeks prior to study intervention administration and until at least 6 months after study intervention administration.
* Known hypersensitivity to any component of the study intervention.
* Previous hypersensitivity or severe adverse reaction following administration of a mAb.
* Acute (time-limited) or febrile (temperature = 38.0°C [100.4ºF]) illness/infection on day prior to or day of planned dosing; participants excluded for transient acute illness may be dosed if illness resolves within the screening period or may be rescreened once.
* Blood drawn in excess of a total of 450 mL (1 unit) for any reason within 30 days prior to Visit 1.
* Clinically significant bleeding disorder (eg, factor deficiency, coagulopathy, or platelet disorder), or prior history of significant bleeding or bruising following IM injections or venipuncture.
* Receipt of immunoglobulin (non-COVID related) or blood products within 6 months prior to Visit 1.
* Previous receipt of a mAb against SARS-CoV-2.
* Receipt of a COVID-19 vaccine within 3 months prior to Visit 1.
* Receipt of a COVID-19 antiviral for prophylaxis within 3 months prior to Visit 1
* COVID-19 within 3 months prior to Visit 1 (confirmed either by laboratory testing or a rapid test [including at home testing]).
* Receipt of any IMP in the preceding 90 days or expected receipt of IMP during the period of study follow-up, or concurrent participation in another interventional study.
* Known or suspected congenital or acquired immunodeficiency, or receipt of immunosuppressive therapy, including any course of glucocorticoid therapy exceeding 2 weeks of prednisone or equivalent at a dose of 20 mg daily or every other day within 6 months prior to screening.
* Active infection with hepatitis B or C.
* Serum creatinine, AST, or ALT above 1.5 × ULN at screening
* History of malignancy other than treated non-melanoma skin cancers or locally-treated cervical cancer in previous 5 years.
Parent study - Main Cohort Participants (Phase III):
Parent study - Main Cohort Inclusion Criteria:
* Participant must be 12 years of age or older at the time of signing the informed consent.
* Negative rapid antigen test prior to dosing at Visit 1.
* Weight = 40 kg at screening.
* Participants must satisfy at least 1 of the following risk factors at enrollment:
* Have solid tumor cancer and be on active immunosuppressive treatment
* Have hematologic malignancy
* Transplant participants must satisfy at least one of the following:
1. Have had a solid organ transplant within 2 years and / or
2. Had a hematopoietic stem cell transplant within 2 years and / or
3. Who have chronic graft-versus-host disease
4. Participants who previously had a solid organ transplant or hematopoietic stem cell transplant more than 2 years prior to Visit 1 may also be eligible based on the inclusion criterion for immunosuppressive treatment
* Are actively taking immunosuppressive medicines (eg, are using corticosteroids [ie, = 20 mg prednisone or equivalent per day when administered for = 2 weeks], high dose alkylating agents, antimetabolites, transplant-related immunosuppressive drugs, cancer chemotherapeutic agents classified as severely immunosuppressive [eg, Bruton's tyrosine kinase inhibitors], tumor-necrosis blockers, or other immunosuppressive or immunomodulatory biologic agents (eg, for rheumatic diseases)
* Received chimeric antigen receptor T cell therapy
* Within 1 year of receiving B-cell depleting therapies (eg, rituximab, ocrelizumab, ofatumumab, alemtuzumab)
* Have a moderate or severe primary (eg, DiGeorge syndrome) or secondary (eg, hemodialysis) immunodeficiency
* Advanced or untreated HIV infection (people with HIV and CD4 cell counts < 200/mm3 within 6 months of Visit 1, history of an AIDS-defining illness without immune reconstitution, or clinical manifestations of symptomatic HIV)
* Medically stable defined as disease not requiring significant change in maintenance therapy or hospitalization for worsening disease or any recent CV event (eg, acute myocardial infarction, thromboembolic event) during the 1 month prior to enrollment, with no acute change in condition at the time of study enrollment as judged by the Investigator and no expected changes at the time of the enrollment.
* Able to understand and comply with all study requirements/procedures (if applicable, with assistance by caregiver, surrogate, or legally authorized representative or equivalent representative as locally defined), including those at Illness Visits, based on the assessment of the Investigator.
Parent study - Main Cohort
* Women who are pregnant, lactating, or of childbearing potential and not using a highly effective method of contraception or abstinence from at least 4 weeks prior to study intervention administration and until at least 6 months after study intervention administration. Note: female participants aged > 12 years will be considered to be a woman of childbearing potential.
* Known hypersensitivity to any component of the study intervention.
* Previous hypersensitivity or severe adverse reaction following administration of a mAb.
* Acute (time-limited) or febrile (temperature = 38.0°C [100.4ºF]) illness/infection on day prior to or day of planned dosing; participants excluded for transient acute illness may be dosed if illness resolves and may be rescreened for enrollment once.
* Blood drawn in excess of a total of 450 mL (1 unit) for any reason within 30 days prior to Visit 1.
* Clinically significant bleeding disorder (eg, factor deficiency, coagulopathy, or platelet disorder), or prior history of significant bleeding or bruising following IM injections or venipuncture.
* Receipt of IV or SC immunoglobulin within 6 months prior to Visit 1 or expected to receive IV or SC immunoglobulin 6 months after dosing.
* Receipt of convalescent COVID-19 plasma treatment within 6 months prior to Visit 1.
* Previous receipt of a mAb against SARS-CoV-2 within 6 months prior to Visit 1.
* Receipt of a COVID-19 vaccine within 3 months prior to Visit 1.
* Receipt of a COVID-19 antiviral for prophylaxis within at least 2 weeks prior to Visit 1.
* COVID-19 within 3 months prior to Visit 1 (confirmed either by laboratory testing or a rapid test [including at home testing]).
* Receipt of any IMP in the preceding 90 days or expected receipt of IMP during the period of study follow-up, or concurrent participation in another interventional study except where the participant ceased IMP treatment >90 days and is in the follow-up period of the study and not expected to receive further IMP).
Sub-study - Inclusion Criteria (Phase II):
Sub-study - Sentinel Safety Cohort Inclusion Criteria:
* Healthy, defined according to medical history, physical examination, baseline safety laboratory tests, and screening parameters, according to the judgment of the Investigator.
* Participants must be 18 to 55 years at the time of signing the informed consent.
* Weight = 45 kg and = 110 kg at screening.
Sub-study - Full Sub-study Cohort Inclusion Criteria:
* Immunocompromised or immunocompetent, including healthy participants, with all degrees of SARS-CoV-2 infection risk, will be enrolled following completion of Sentinel Safety Cohort enrolment.
* Participants must be 18 years of age or older at the time of signing the informed consent.
* Weight = 40 kg at screening.
Sub-study - Sub-study Sentinel Safety Cohort and Full Sub-study Cohort Inclusion Criteria:
* Written informed consent and any locally required authorization (eg, HIPAA in the US) obtained from the participant prior to performing any protocol-related procedures, including screening evaluations.
* Negative rapid antigen test for SARS-CoV-2 prior to dosing at Visit 1.
* Medically stable defined as disease not requiring significant change in maintenance therapy or hospitalization for worsening disease or any recent cardiovascular event (eg, acute myocardial infarction, thromboembolic event) during the 1 month prior to enrollment, with no acute change in condition at the time of study enrollment as judged by the Investigator and no expected changes at the time of the enrollment.
* Able to understand and comply with all study requirements/procedures (if applicable, with assistance by caregiver, surrogate, or legally authorized representative or equivalent representative as locally defined), based on the assessment of the Investigator.
Sub-study - Exclusion Criteria (Phase II):
Sub-study - Sentinel Safety Cohort
* Active infection with hepatitis B or C.
* Serum creatinine, AST, or ALT above 1.5 × ULN at screening.
* History of malignancy other than treated non-melanoma skin cancers or locally-treated cervical cancer in previous 5 years.
Sub-study - Sentinel Safety Cohort and Full Sub-study Cohort
* Receipt of EVUSHELD (AZD7442) within 12 months prior to Visit 1.
* Women who are pregnant, lactating, or of childbearing potential and not using a highly effective method of contraception or abstinence from at least 4 weeks prior to study intervention administration and until at least 6 months after study intervention administration. Note: female participants aged > 12 years will be considered to be a woman of childbearing potential.
* Known hypersensitivity to any component of the study intervention.
* Previous hypersensitivity or severe adverse reaction following administration of a mAb.
* Acute (time-limited) or febrile (temperature = 38.0°C [100.4ºF]) illness/infection on day prior to or day of planned dosing; participants excluded for transient acute illness may be dosed if illness resolves and may be rescreened for enrollment once.
* Blood drawn in excess of a total of 450 mL (1 unit) for any reason within 30 days prior to Visit 1.
* Clinically significant bleeding disorder (eg, factor deficiency, coagulopathy, or platelet disorder), or prior history of significant bleeding or bruising following IM injections or venipuncture.
* Has human immunodeficiency virus infection.
* Receipt of IV or SC immunoglobulin or blood products within 6 months prior to Visit 1 and expected to receive IV or SC immunoglobulin or blood products 6 months after dosing.
* Receipt of a COVID-19 vaccine within 3 months prior to Visit 1.
* Receipt of a COVID-19 antiviral for prophylaxis within at least 2 weeks prior to Visit 1.
* COVID-19 within 3 months prior to Visit 1 (confirmed either by laboratory RT-PCR testing or a rapid antigen test [including at-home testing]).
* Receipt of any IMP in the preceding 90 days or expected receipt of IMP during the period of study follow-up, or concurrent participation in another interventional study (except where the participant ceased IMP treatment > 90 days and is in the follow-up period of the study and not expected to receive further IMP).
Query!
Study design
Purpose of the study
Prevention
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Active, not recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
16/12/2022
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
18/02/2025
Query!
Actual
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
3882
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
Research Site - Melbourne
Query!
Recruitment hospital [2]
0
0
Research Site - Murdoch
Query!
Recruitment hospital [3]
0
0
Research Site - Parkville
Query!
Recruitment hospital [4]
0
0
Research Site - Raymond Terrace
Query!
Recruitment hospital [5]
0
0
Research Site - Sippy Downs
Query!
Recruitment hospital [6]
0
0
Research Site - West Perth
Query!
Recruitment postcode(s) [1]
0
0
3000 - Melbourne
Query!
Recruitment postcode(s) [2]
0
0
3004 - Melbourne
Query!
Recruitment postcode(s) [3]
0
0
6150 - Murdoch
Query!
Recruitment postcode(s) [4]
0
0
3050 - Parkville
Query!
Recruitment postcode(s) [5]
0
0
4101 - Raymond Terrace
Query!
Recruitment postcode(s) [6]
0
0
4556 - Sippy Downs
Query!
Recruitment postcode(s) [7]
0
0
6005 - West Perth
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arizona
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Arkansas
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
California
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Colorado
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Connecticut
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
District of Columbia
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Florida
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Georgia
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Idaho
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Illinois
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Indiana
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Iowa
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Kansas
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Kentucky
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Louisiana
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Maryland
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Massachusetts
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
Michigan
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
Minnesota
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
Missouri
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
Montana
Query!
Country [23]
0
0
United States of America
Query!
State/province [23]
0
0
Nebraska
Query!
Country [24]
0
0
United States of America
Query!
State/province [24]
0
0
Nevada
Query!
Country [25]
0
0
United States of America
Query!
State/province [25]
0
0
New Hampshire
Query!
Country [26]
0
0
United States of America
Query!
State/province [26]
0
0
New Jersey
Query!
Country [27]
0
0
United States of America
Query!
State/province [27]
0
0
New Mexico
Query!
Country [28]
0
0
United States of America
Query!
State/province [28]
0
0
New York
Query!
Country [29]
0
0
United States of America
Query!
State/province [29]
0
0
North Carolina
Query!
Country [30]
0
0
United States of America
Query!
State/province [30]
0
0
Ohio
Query!
Country [31]
0
0
United States of America
Query!
State/province [31]
0
0
Pennsylvania
Query!
Country [32]
0
0
United States of America
Query!
State/province [32]
0
0
Rhode Island
Query!
Country [33]
0
0
United States of America
Query!
State/province [33]
0
0
South Carolina
Query!
Country [34]
0
0
United States of America
Query!
State/province [34]
0
0
Tennessee
Query!
Country [35]
0
0
United States of America
Query!
State/province [35]
0
0
Texas
Query!
Country [36]
0
0
United States of America
Query!
State/province [36]
0
0
Utah
Query!
Country [37]
0
0
United States of America
Query!
State/province [37]
0
0
Virginia
Query!
Country [38]
0
0
United States of America
Query!
State/province [38]
0
0
Washington
Query!
Country [39]
0
0
United States of America
Query!
State/province [39]
0
0
Wisconsin
Query!
Country [40]
0
0
Belgium
Query!
State/province [40]
0
0
Alken
Query!
Country [41]
0
0
Belgium
Query!
State/province [41]
0
0
Liège
Query!
Country [42]
0
0
Canada
Query!
State/province [42]
0
0
Quebec
Query!
Country [43]
0
0
Denmark
Query!
State/province [43]
0
0
Aalborg
Query!
Country [44]
0
0
Denmark
Query!
State/province [44]
0
0
Aarhus
Query!
Country [45]
0
0
Denmark
Query!
State/province [45]
0
0
Hvidovre
Query!
Country [46]
0
0
Denmark
Query!
State/province [46]
0
0
Roskilde
Query!
Country [47]
0
0
Denmark
Query!
State/province [47]
0
0
Svendborg
Query!
Country [48]
0
0
France
Query!
State/province [48]
0
0
Dijon Cedex
Query!
Country [49]
0
0
France
Query!
State/province [49]
0
0
La Roche sur Yon
Query!
Country [50]
0
0
France
Query!
State/province [50]
0
0
Lille
Query!
Country [51]
0
0
France
Query!
State/province [51]
0
0
Nantes
Query!
Country [52]
0
0
France
Query!
State/province [52]
0
0
Nîmes Cedex 9
Query!
Country [53]
0
0
France
Query!
State/province [53]
0
0
Paris cedex 10
Query!
Country [54]
0
0
France
Query!
State/province [54]
0
0
Paris
Query!
Country [55]
0
0
France
Query!
State/province [55]
0
0
Poitiers
Query!
Country [56]
0
0
France
Query!
State/province [56]
0
0
Saint-Etienne Cedex 2
Query!
Country [57]
0
0
France
Query!
State/province [57]
0
0
Strasbourg
Query!
Country [58]
0
0
France
Query!
State/province [58]
0
0
Toulouse Cedex 9
Query!
Country [59]
0
0
France
Query!
State/province [59]
0
0
Tours
Query!
Country [60]
0
0
Germany
Query!
State/province [60]
0
0
Essen
Query!
Country [61]
0
0
Germany
Query!
State/province [61]
0
0
Hamburg
Query!
Country [62]
0
0
Germany
Query!
State/province [62]
0
0
Hannover
Query!
Country [63]
0
0
Germany
Query!
State/province [63]
0
0
Köln
Query!
Country [64]
0
0
Germany
Query!
State/province [64]
0
0
Mainz
Query!
Country [65]
0
0
Israel
Query!
State/province [65]
0
0
Petah Tikva
Query!
Country [66]
0
0
Israel
Query!
State/province [66]
0
0
Ramat Gan
Query!
Country [67]
0
0
Korea, Republic of
Query!
State/province [67]
0
0
Gyeonggi-do
Query!
Country [68]
0
0
Korea, Republic of
Query!
State/province [68]
0
0
Seoul
Query!
Country [69]
0
0
Malaysia
Query!
State/province [69]
0
0
Bandar Sunway
Query!
Country [70]
0
0
Malaysia
Query!
State/province [70]
0
0
Kuala Lumpur
Query!
Country [71]
0
0
Malaysia
Query!
State/province [71]
0
0
Kuching
Query!
Country [72]
0
0
Malaysia
Query!
State/province [72]
0
0
Seberang Jaya
Query!
Country [73]
0
0
Poland
Query!
State/province [73]
0
0
Krakow
Query!
Country [74]
0
0
Poland
Query!
State/province [74]
0
0
Skórzewo
Query!
Country [75]
0
0
Singapore
Query!
State/province [75]
0
0
Singapore
Query!
Country [76]
0
0
Spain
Query!
State/province [76]
0
0
Badalona
Query!
Country [77]
0
0
Spain
Query!
State/province [77]
0
0
Barcelona
Query!
Country [78]
0
0
Spain
Query!
State/province [78]
0
0
Cordoba
Query!
Country [79]
0
0
Spain
Query!
State/province [79]
0
0
Madrid
Query!
Country [80]
0
0
Spain
Query!
State/province [80]
0
0
Marbella (Málaga)
Query!
Country [81]
0
0
Spain
Query!
State/province [81]
0
0
Mérida
Query!
Country [82]
0
0
Spain
Query!
State/province [82]
0
0
Pozuelo de Alarcón
Query!
Country [83]
0
0
Spain
Query!
State/province [83]
0
0
Valladolid
Query!
Country [84]
0
0
Spain
Query!
State/province [84]
0
0
Vigo
Query!
Country [85]
0
0
Taiwan
Query!
State/province [85]
0
0
Taichung
Query!
Country [86]
0
0
Taiwan
Query!
State/province [86]
0
0
Taipei
Query!
Country [87]
0
0
Thailand
Query!
State/province [87]
0
0
Bangkok
Query!
Country [88]
0
0
Thailand
Query!
State/province [88]
0
0
Khon Kaen
Query!
Country [89]
0
0
Thailand
Query!
State/province [89]
0
0
Muang
Query!
Country [90]
0
0
United Arab Emirates
Query!
State/province [90]
0
0
Abu Dhabi
Query!
Country [91]
0
0
United Kingdom
Query!
State/province [91]
0
0
Bristol
Query!
Country [92]
0
0
United Kingdom
Query!
State/province [92]
0
0
Edinburgh
Query!
Country [93]
0
0
United Kingdom
Query!
State/province [93]
0
0
Harrow
Query!
Country [94]
0
0
United Kingdom
Query!
State/province [94]
0
0
Leeds
Query!
Country [95]
0
0
United Kingdom
Query!
State/province [95]
0
0
Liverpool
Query!
Country [96]
0
0
United Kingdom
Query!
State/province [96]
0
0
London
Query!
Country [97]
0
0
United Kingdom
Query!
State/province [97]
0
0
Manchester
Query!
Country [98]
0
0
United Kingdom
Query!
State/province [98]
0
0
Oxford
Query!
Country [99]
0
0
United Kingdom
Query!
State/province [99]
0
0
Sheffield
Query!
Country [100]
0
0
United Kingdom
Query!
State/province [100]
0
0
Torpoint
Query!
Country [101]
0
0
United Kingdom
Query!
State/province [101]
0
0
Truro
Query!
Country [102]
0
0
Vietnam
Query!
State/province [102]
0
0
Hanoi
Query!
Country [103]
0
0
Vietnam
Query!
State/province [103]
0
0
Hochiminh city
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
AstraZeneca
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
AZD3152, a single mAb, is being developed to have broad neutralizing activity across known SARS-CoV-2 variants of concern for pre-exposure prophylaxis of COVID-19.
The aim of the Phase I/III study (Parent Study) will be to evaluate the safety, efficacy and neutralizing activity of AZD3152 compared with comparator for pre exposure prophylaxis of COVID-19, and separately evaluate the safety and PK of AZD5156, a combination of AZD3152 and AZD1061.
Sub-study:
This Phase II sub-study of SUPERNOVA will assess the safety, PK, and predicted neutralizing activity of AZD3152 compared with EVUSHELD for pre-exposure prophylaxis of COVID-19.
Query!
Trial website
https://clinicaltrials.gov/study/NCT05648110
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/study/NCT05648110
Download to PDF